An Innovative Canadian Pharmaceutical Company

Revenue Projected at $160,000,000 by 2025

Sponsored
Message: AGORACOM Small Cap 60: Valeo Pharma Extremely Pleased With Both Public and Private Reimbursement Status of Asthma and Blood Thinner Drugs

AGORACOM Small Cap 60: Valeo Pharma Extremely Pleased With Both Public and Private Reimbursement Status of Asthma and Blood Thinner Drugs

posted on Nov 19, 2021 01:47PM

Share
New Message
Please login to post a reply